USPTO awards Immunitor vital patent for viral vaccine

Insusceptible Network Ltd. (Pink Sheets:IMMFF), advises that its potential acquirement, Immunitor USA Inc., has been issued a pivotal flagrant aside the U.S. Transparent and Trademark Backing (USPTO).

The control (US 7,838,006 Viral vaccine make-up, get ready and methods of reject) contains claims covering the formulation of trouble for Immunitor's lead product, V5. The clear also covers the treat of making and use of the theme recompense treating and preventing the girl range of infectious diseases. Immunitor was times awarded a U.S. franchise covering another out fuse specifically designed for treatment of AIDS (US 7,384,637).

According to Vichai Jirathitikal, the president inventor on these two patents, The USPTO has validated the novelty and utility of Immunitor's technology and its use in the treatment and prophylaxis of a number of most dissimilar diseases and conditions. The co-inventor, Aldar Bourinbaiar, Immunitor's CEO, added: With the issuance o f these two patents, our about programs are more protected, significantly enhancing their commercial value.

To the programme naturally of the actors's advancement, Immunitor has achieved a forthright and wise intellectual-property position in the orally delivered immunotherapeutics area. The company's control portfolio now includes more than eight pending patents (including two international), with at least two dozen thorough publications in the peer-reviewed medical hand-outs describing individual aspects of the technology in communicable and autoimmune diseases, cancer, and metabolic diseases such as atherosclerosis and obesity. The combined annual store for these and connected indications is wind up to $100 billion.

Immunitor is the industry chairlady in tableted said vaccines and immunotherapies. During the past three years Immunitor completed two aspect II clinical trials using V5 suited for treatment of continuing hepatitis B and hepatitis C. This year I mmunitor seized upon an unexpected clinical outcome, which revealed the intriguing potential of V5 in curing tuberculosis in almost 95% of patients within a person month. The results of the elementary cipro hc ortic trial in patients with tuberculosis who were co-infected with hepatitis C virus and HIV were published in October issue of Periodical of Vaccines and Vaccination (http://www.omicsonline.org/2157-7560/2157-7560-1-103.php). Forbearing enrollment in compensation two additional condition 2b placebo-controlled trials involving 120 patients with difficult-to-treat forms of tuberculosis has been unprejudiced completed in Ukraine and results are anticipated in antiquated 2011.

To date, all clinical trials of V5 prepare provided strong indication of an noteworthy cover profile and provided insights into the consummate efficacy that will sway Immunitor in the sketch out of follow-on hepatitis and tuberculosis s tudies, which are at times being arranged in South Africa, Pakistan, India and China.

Unsusceptible Network is continuing its business toward meeting the pre-conditions as a replacement for termination of a combination or correspond to minutes with Immunitor. Distinct aspects of the updated corporation and its anticipated transactions will be announced first in December 2010.